SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

LAVA THERAPEUTICS N.V.

(Name of Issuer)

Common shares, Euro 0.12 nominal value per share

(Title of Class of Securities)

N51517105

(CUSIP Number)

Edwin de Graaf
Cooperatieve Gilde Healthcare IV U.A., Stadsplateau 36
Utrecht, P7, 3521 AZ
31 30 219 2565

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/20/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

N51517105

Name of reporting person

Cooperatieve Gilde Healthcare IV U.A.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,014,751.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,014,751.00

Aggregate amount beneficially owned by each reporting person

1,014,751.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

3.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

N51517105

Name of reporting person

Gilde Healthcare IV Management B.V.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,014,751.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,014,751.00

Aggregate amount beneficially owned by each reporting person

1,014,751.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

3.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

N51517105

Name of reporting person

Gilde Healthcare Holding B.V.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,014,751.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,014,751.00

Aggregate amount beneficially owned by each reporting person

1,014,751.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

3.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

N51517105

Name of reporting person

Manapouri B.V.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,014,751.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,014,751.00

Aggregate amount beneficially owned by each reporting person

1,014,751.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

3.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

N51517105

Name of reporting person

Martemanshurk B.V.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,014,751.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,014,751.00

Aggregate amount beneficially owned by each reporting person

1,014,751.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

3.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common shares, Euro 0.12 nominal value per share

(b)

Name of Issuer:

LAVA THERAPEUTICS N.V.

(c)

Address of Issuer's Principal Executive Offices:

Yalelaan 62, Utrecht, NETHERLANDS , 3584 CM.

Item 1 Comment:

This Amendment No. 3 ("Amendment No. 3") to Schedule 13D amends the initial Statement on Schedule 13D filed on March 21, 2021, as amended by Amendment No. 1 filed on October 14, 2025 and Amendment No. 2 filed on October 17 (as so amended, the "Schedule 13D"), relating to the common shares, nominal value Euro 0.12 per share ("Common Shares"), of LAVA Therapeutics N.V., a Netherlands corporation (the "Issuer"). This Amendment No. 3 reflects, among other things, the sales of Common Shares by Cooperatieve Gilde Healthcare IV U.A. ("Gilde Healthcare"). Only those items that are hereby reported are amended; all other items reported in the Schedule 13D remain unchanged. Capitalized terms used but not defined in this Amendment No. 3 shall have the same meanings ascribed to them in the Schedule 13D.

Item 4.

Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: Between October 20, 2025 and October 21, 2025, Gilde Healthcare sold an aggregate of 1,933,030 Common Shares of the Issuer in open market transactions.

Item 5.

Interest in Securities of the Issuer

(a)

According to the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on August 13, 2025, there were 26,305,295 Common Shares outstanding as of August 8, 2025. Gilde Healthcare is the record holder of an aggregate of 1,014,751 Common Shares, which represents beneficial ownership of approximately 3.9% of the outstanding Common Shares as of August 8, 2025. GHCIVM, as the manager of Gilde Healthcare, has the power to vote and dispose of securities held by Gilde Healthcare and may be deemed to beneficially own the securities held of record by Gilde Healthcare. As a result, each of the Reporting Persons may beneficially own 1,014,751 Common Shares, or approximately 3.9% of the outstanding Common Shares.

(b)

Each Reporting Person has shared power to vote and dispose of 1,014,751 Common Shares.

(c)

On October 20, 2025, Gilde Healthcare sold 1,000,000 Common Shares at a weighted average price per share of $1.4647 for aggregate proceeds of approximately $1,464,700.00. On October 21, 2025, Gilde Healthcare sold 933,030 Common Shares at a weighted average price per share of $1.4664 for aggregate proceeds of approximately $1,368,195.19.

(e)

As of October 21, 2025, the Reporting Persons ceased to beneficially own more than 5% of the Issuer's outstanding Common Shares.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cooperatieve Gilde Healthcare IV U.A.

Signature:	/s/ Edwin de Graaf
Name/Title:	Edwin de Graaf/Managing Director of Gilde Healthcare IV Management B.V., as Manager of Cooperatieve Gilde Healthcare IV U.A.
Date:	10/22/2025

Gilde Healthcare IV Management B.V.

Signature:	/s/ Edwin de Graaf
Name/Title:	Edwin de Graaf/Managing Director
Date:	10/22/2025

Gilde Healthcare Holding B.V.

Signature:	/s/ Edwin de Graaf
Name/Title:	Edwin de Graaf/Managing Director
Date:	10/22/2025

Manapouri B.V.

Signature:	/s/ Edwin de Graaf
Name/Title:	Edwin de Graaf/Managing Director
Date:	10/22/2025

Martemanshurk B.V.

Signature:	/s/ Pieter van der Meer
Name/Title:	Pieter van der Meer/Managing Director
Date:	10/22/2025

Amendment: SEC Form SCHEDULE 13D/A filed by LAVA Therapeutics N.V.